RxDoctor Payments DataLook up a doctor →

Luis Annoni Suau, MD

Clinical Cardiac Electrophysiology · Hudson, FLNPI 1073501789

Payments from drug & device makers

$182,458in general payments, 2019–2025

Across 441 payments — averaging $413.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shimadzu Precision Instruments, Inc.$108K
  • Boston Scientific$44K
  • Angiodynamics, Inc.$21K
  • Medical Device Business Services, Inc.$3K
  • Biosense Webster, Inc.$2K
  • Atricure, Inc.$1K
  • plus $4K from 28 others

What the payments were for

  • Consulting fees$142,00078%
  • Travel & lodging$6,7874%
  • Food & beverage$13,0047%
  • Other$20,66711%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$182,458 in reported general payments places this provider in the 80th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$251,708
Medicare patients
488
Services billed
2,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban165$174,042
XareltoRivaroxaban115$134,171
MultaqDronedarone Hcl46$56,590
Dofetilide109$27,845
Amiodarone Hcl307$10,306
Midodrine Hcl64$8,447
Metoprolol Succinate339$7,609
Dabigatran EtexilateDabigatran Etexilate Mesylate17$7,568
Flecainide Acetate140$6,952
Propafenone Hcl ErPropafenone Hcl17$6,305
Bisoprolol Fumarate174$5,443
Clonidine34$4,891
ClopidogrelClopidogrel Bisulfate161$2,551
Sucralfate44$1,325
Fludrocortisone Acetate38$982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$104$174,042165 claims
Johnson & JohnsonXarelto$354$134,171115 claims
Sanofi-aventis U.S. LLCMultaq$173$56,59046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Hudson

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →